论文部分内容阅读
目的:探讨为慢性阻塞性肺病合并呼衰患者应用无创正压通气治疗的实际效果,评价其优越性。方法:选取2013年1月~11月于我院就诊的25例慢性阻塞性肺病合并呼衰患者,给予无创通气治疗,将其作为本研究的观察组,选取同时期于我院接受常规通气治疗的慢性阻塞性肺病合并呼衰患者20例,将其作为对照组,对比两组临床预后。结果:①与治疗前对比,两组PaCO2(二氧化碳分压:观察组为50.8±8.0mmHg,对照组为67.9±8.9mmHg)、PaO2(动脉血氧分压:观察组为77.2±17.8mmHg,对照组为57.9±17.0mmHg)、pH(氢离子浓度指数:观察组为7.30±0.12,对照组为7.27±0.07)均有所改善,且两组差异具有统计学意义(P<0.05);②并发症:观察组VAP(呼吸机相关性肺炎)发生率12%,对照组为30%,观察组明显低于对照组,两组差异显著(P<0.05)。结论:为慢性阻塞性肺病合并呼衰患者应用无创正压通气治疗,可有效改善患者血气指标,降低VAP发生率,改善预后,提高患者生存质量。
Objective: To investigate the practical effect of noninvasive positive pressure ventilation in patients with chronic obstructive pulmonary disease and respiratory failure, and to evaluate their superiority. Methods: Twenty-five patients with chronic obstructive pulmonary disease and respiratory failure who were treated in our hospital from January 2013 to November 2013 were enrolled in this study. Non-invasive ventilation was used as the observation group in this study. During the same period, we received routine ventilation Of chronic obstructive pulmonary disease patients with respiratory failure in 20 cases, as a control group, compared two groups of clinical prognosis. Results: ①Compared with before treatment, PaCO2 (partial pressure of carbon dioxide: observation group 50.8 ± 8.0mmHg, control group 67.9 ± 8.9mmHg), PaO2 (arterial partial pressure of oxygen: observation group 77.2 ± 17.8mmHg, control Group (57.9 ± 17.0mmHg)), pH (hydrogen ion concentration index: 7.30 ± 0.12 in the observation group and 7.27 ± 0.07 in the control group), and the difference between the two groups was statistically significant (P <0.05) Symptoms: The incidence of VAP (ventilator-associated pneumonia) was 12% in the observation group and 30% in the control group, which was significantly lower in the observation group than in the control group (P <0.05). Conclusion: The application of non-invasive positive pressure ventilation in patients with chronic obstructive pulmonary disease and respiratory failure can effectively improve the blood gas index, reduce the incidence of VAP, improve the prognosis and improve the quality of life of patients.